Table 4 The relationship between mGPS, NLS and 5-year CSS and OS rates in patients undergoing potentially curative resection of TNM stage II (n = 391) and III (n = 294) colonic cancer

From: The prognostic value of systemic inflammation in patients undergoing surgery for colon cancer: comparison of composite ratios and cumulative scores

 

Stage II (n = 322)

  

Stage II (n = 322)

  
 

mGPS 0

mGPS 1/2

 

mGPS 0–2

mGPS 0

mGPS 1/2

 

mGPS 0–2

 

n

5-year CSS (%)

n

5-year CSS (%)

n

 

n

5-year OS (%)

n

5-year OS (%)

n

 

NPS 0

147 (85%)

88.4 (0.03)

78 (52%)

82.1 (0.04)

225

86.2 (0.02)

147 (85%)

66.7 (0.04)

78 (52%)

58.7 (0.06)

225

61.3 (0.03)

NPS 1/2

26 (15%)

69.2 (0.09)

71 (48%)

74.6 (0.05)

97

73.2 (0.05)

26 (15%)

57.7 (0.10)

71 (48%)

43.7 (0.06)

97

47.4 (0.05)

NPS 0–2

173

85.5 (0.03)

149

78.5 (0.03)

322

82.3 (0.02)

173

65.3 (0.04)

149

47.7 (0.04)

322

57.1 (0.03)

 

Stage III (n = 254)

     

Stage III (n = 254)

     

NPS 0

120 (82%)

70.0 (0.04)

50 (46%)

60.0 (0.07)

170

67.1 (0.04)

120 (82%)

54.2 (0.05)

50 (46%)

44.0 (0.07)

170

51.2 (0.04)

NPS 1/2

25 (18%)

64.0 (0.10)

59 (54%)

57.6 (0.07)

84

59.5 (0.05)

25 (18%)

48.0 (0.10)

59 (54%)

32.2 (0.06)

84

36.9 (0.05)

NPS 0–2

145

69.0 (0.04)

109

58.7 (0.05)

254

64.6 (0.03)

145

53.1 (0.04)

109

37.6 (0.05)

254

46.5 (0.03)

  1. Values are expressed as % (standard error) survival not calculated if n < 10.
  2. CSS cancer-specific survival, OS overall survival, TNM tumour node metastasis, NLS neutrophil–lymphocyte score, mGPS modified Glasgow prognostic score, NPS neutrophil–platelet score
Back to article page